Search This Blog

Friday 22 January 2010

Sibutramine (Reductil)



داروی ضد چاقی
Sibutramine (Reductil)
بعد از این در کشورهای اروپایی برای کاهش وزن تجویز نمیشود. اشخاصی که اکنون از این دارو برای کمک به کاهش وزن استفاده میکنند باید با مشورت با پزشک خود از مصرف این دارو خوداری کنند و راهکارهای دیگری را برای کاهش وزن دنبال نمایند



The licence for the anti-obesity drug sibutramine (Reductil) has been suspended across Europe (including UK).

The MHRA and European Medicines Agency (EMA) recommendations are as follows:
Pharmacists should no longer dispense sibutramine-containing medicines.
Doctors should stop prescribing sibutramine-containing medicines to obese or overweight patients. They should also review the treatment of patients currently treated with the medicine.
Patients who are taking a medicine containing sibutramine to help them to lose weight should make an appointment with their doctor at the next convenient time to discuss alternative measures to lose weight.
Patients who wish to stop treatment before seeing their doctor can do so at any time.
Patients who have any questions should speak to their doctor or pharmacist.
The MHRA has indicated that there are no health implications if people wish to stop treatment before seeing their doctor.

Extracted from the Royal Pharmaceutical Society's email alert